Susan Rosencrance
FDA, United States
Director, Office of Lifecycle Drug Products, OPQ, CDER
Dr. Susan Rosencrance presently heads FDA's Office of Lifecycle Drug Products within the Office of Pharmaceutical Quality (OPQ). She provides executive leadership by overseeing and directing scientific review programs and activities related to evaluating drug product quality throughout the lifecycle (brand to generic). Susan has a long history with the FDA working in various roles within CDER. Prior to joining the Agency she worked at Merck's R&D labs in a new drug discovery program. She holds a Ph.D. in Chemistry from American University and completed her dissertation research in the Laboratory of Biophysical Chemistry at the National Institutes of Health (NIH).